Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.

Cancer biology & therapy - 1 Aug 2014

Chen Wei, Hu Qi-Da, Xia Xue-Feng, Liang Chao, Liu Hao, Zhang Qi, Ma Tao, Liang Feng, Liang Ting-Bo

Abstract excerpt

The synergistic effect of combined drug therapy provides an enhanced treatment for advanced liver cancer. We aimed to investigate the underlying mechanism of cetuximab sensitization by rapamycin in hepatoma cells. Four hepatoma cell lines, HepG2, HuH7, SNU-387, and SNU-449, were treated with cetuximab or cetuximab plus rapamycin and growth inhibition was evaluated by measuring relative cell viability and cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cell Hypoxia

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Drug Synergism

Share to Epithelial-Mesenchymal Transition

Share to Sirolimus

Share to TOR Serine-Threonine Kinases

Share to Vimentin

Source

Open in PubMed Open full text

Identifiers

PMID: 24800850
DOI: 10.4161/cbt.29113
PMCID: PMC4119084

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapamycin enhances cetuximab cytotoxicity by inhibiting mTOR-mediated drug resistance in mesenchymal hepatoma cells.PMID 24800850Read ↗

Rapamycin Response in Tumorigenic and Non-Tumorigenic Hepatic Cell LinesSemantic proximity Read ↗

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab.Semantic proximity Read ↗

Cetuximab promotes SN38 sensitivity via suppression of heat shock protein 27 in colorectal cancer cells with wild-type RAS.Semantic proximity Read ↗

Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.Semantic proximity Read ↗

Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.Semantic proximity Read ↗

Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.Semantic proximity Read ↗

MiR-199a-3p enhances cisplatin sensitivity of cholangiocarcinoma cells by inhibiting mTOR signaling pathway and expression of MDR1Semantic proximity Read ↗

Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.Semantic proximity Read ↗

Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway.Semantic proximity Read ↗

Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.Semantic proximity Read ↗

Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.Semantic proximity Read ↗

Epithelial to mesenchymal transition is associated with rapamycin resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.